These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 209804)

  • 1. Experimental hyper-beta-lipoproteinemia and its amelioration by a novel hypolipidemic agent.
    Kobayakawa T; Osuga K; Yasuda H
    Atherosclerosis; 1978 Jul; 30(3):219-25. PubMed ID: 209804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of a new drug MK 185 with clofibrate in the treatment of hyperlipidaemias.
    Jepson EM; Small E; Grayson MF; Bance G; Billimoria JD
    Atherosclerosis; 1972; 16(1):9-14. PubMed ID: 4341723
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on hypoxic dyslipidaemia. Effect of lipid modulating drugs.
    Mälkönen M; Muona M; Manninen V
    Acta Med Scand Suppl; 1982; 668():130-5. PubMed ID: 6963088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year study of the effect of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
    Olsson AG; Lang PD
    Atherosclerosis; 1978 Dec; 31(4):429-33. PubMed ID: 215175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response study of bezafibrate on serum lipoprotein concentrations in hyperlipoproteinanemia.
    Olsson AG; Lang PD
    Atherosclerosis; 1978 Dec; 31(4):421-8. PubMed ID: 215174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
    Kesäniemi YA; Grundy SM
    JAMA; 1984 May; 251(17):2241-6. PubMed ID: 6368883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypolipidemic activity of substances structurally close to penphenone in rats and mice].
    Polikarpova LI; Reznik SE; Ryzhenkov VV; Khechinashvili GG; Petrova LA
    Vopr Med Khim; 1978; 24(6):835-9. PubMed ID: 216145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of several hypolipidemic agents related to clofibrate.
    Beaumont V; Buxtorf JC; Jacotot B; Beaumont JL
    Atherosclerosis; 1974; 20(2):141-53. PubMed ID: 4369878
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition.
    Föger B; Tröbinger G; Ritsch A; Lechleitner M; Hopferwieser T; Menzel HJ; Utermann G; Pfeiffer KP; Patsch JR
    Atherosclerosis; 1995 Oct; 117(2):253-61. PubMed ID: 8801871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihyperlipidaemic agents.
    Witte EC
    Prog Med Chem; 1975; 11():119-92. PubMed ID: 165566
    [No Abstract]   [Full Text] [Related]  

  • 11. The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug.
    Arnold A; McAuliff JP; Powers LG; Phillips DK; Beyler AL
    Atherosclerosis; 1979 Feb; 32(2):155-63. PubMed ID: 454514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating lipid disorders.
    Manninen V; Mälkönen M; Tuomilehto J
    Am Heart J; 1979 May; 97(5):674-6. PubMed ID: 219673
    [No Abstract]   [Full Text] [Related]  

  • 13. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of BR-931, a new hypolipidemic agent that increases high-density lipoproteins.
    Sirtori CR; Gomarasca P; D'Atri G; Cerutti S; Tronconi G; Scolastico C
    Atherosclerosis; 1978 May; 30(1):45-56. PubMed ID: 209796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Constellation of lipoproteins in patients with hyperlipoproteinemia and in rabbits fed a cholesterol diet with reference to vascular permeability].
    Herrmann W; Reuter W
    Z Gesamte Inn Med; 1977 Dec; 32(24):682-2. PubMed ID: 204118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The common hyperlipoproteinemias: an understanding of disease mechanisms and their control.
    Fisher WR; Truitt DH
    Ann Intern Med; 1976 Oct; 85(4):497-508. PubMed ID: 184730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypolipidemic effect of a new aryloxy compound, S-8527, in experimental animals.
    Suzuki K; Aono S; Nakatani H
    Jpn J Pharmacol; 1974 Jun; 24(3):407-14. PubMed ID: 4449146
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of clofibrate on lipoprotein-lipids in patients with type IV hyperlipoproteinaemia (author's transl)].
    Weisweiler P; Schwandt P
    Klin Wochenschr; 1977 Aug; 55(16):791-4. PubMed ID: 198601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hypertriglyceridemia with tibric acid and clofibrate. Cross-over studies, effects on lipoproteins and absence of post-drug rebound.
    Smith FR; Noble RP; Goodman DS
    Atherosclerosis; 1978 Mar; 29(3):345-54. PubMed ID: 666884
    [No Abstract]   [Full Text] [Related]  

  • 20. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.